Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H15ClN2O4S2 |
| Molecular Weight | 434.916 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CCCC1=CC2=CC(Cl)=CC=C2N1S(=O)(=O)C3=CC4=C(C=C3)N=CS4
InChI
InChIKey=OQDQIFQRNZIEEJ-UHFFFAOYSA-N
InChI=1S/C19H15ClN2O4S2/c20-13-4-7-17-12(8-13)9-14(2-1-3-19(23)24)22(17)28(25,26)15-5-6-16-18(10-15)27-11-21-16/h4-11H,1-3H2,(H,23,24)
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Q07869 Gene ID: 5465.0 Gene Symbol: PPARA Target Organism: Homo sapiens (Human) |
|||
Target ID: Q03181|||Q9BUD4 Gene ID: 5467.0 Gene Symbol: PPARD Target Organism: Homo sapiens (Human) |
|||
Target ID: P37231|||Q15179 Gene ID: 5468.0 Gene Symbol: PPARG Target Organism: Homo sapiens (Human) |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis. | 2016 Dec |
|
| Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension. | 2017 Nov |
|
| Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate. | 2018 Mar 22 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
470315
Created by
admin on Sat Dec 16 12:04:13 GMT 2023 , Edited by admin on Sat Dec 16 12:04:13 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/14/1361
Created by
admin on Sat Dec 16 12:04:13 GMT 2023 , Edited by admin on Sat Dec 16 12:04:13 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB14801
Created by
admin on Sat Dec 16 12:04:13 GMT 2023 , Edited by admin on Sat Dec 16 12:04:13 GMT 2023
|
PRIMARY | |||
|
28Q8AG0PYL
Created by
admin on Sat Dec 16 12:04:13 GMT 2023 , Edited by admin on Sat Dec 16 12:04:13 GMT 2023
|
PRIMARY | |||
|
SUB184623
Created by
admin on Sat Dec 16 12:04:13 GMT 2023 , Edited by admin on Sat Dec 16 12:04:13 GMT 2023
|
PRIMARY | |||
|
EU/3/14/1362(POSITIVE)
Created by
admin on Sat Dec 16 12:04:13 GMT 2023 , Edited by admin on Sat Dec 16 12:04:13 GMT 2023
|
PRIMARY | On 19 November 2014, orphan designation (EU/3/14/1362) was granted by the European Commission to Inventiva, France, for 1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid for the treatment of idiopathic pulmonary fibrosis. | ||
|
C166556
Created by
admin on Sat Dec 16 12:04:13 GMT 2023 , Edited by admin on Sat Dec 16 12:04:13 GMT 2023
|
PRIMARY | |||
|
10474
Created by
admin on Sat Dec 16 12:04:13 GMT 2023 , Edited by admin on Sat Dec 16 12:04:13 GMT 2023
|
PRIMARY | |||
|
68677842
Created by
admin on Sat Dec 16 12:04:13 GMT 2023 , Edited by admin on Sat Dec 16 12:04:13 GMT 2023
|
PRIMARY | |||
|
927961-18-0
Created by
admin on Sat Dec 16 12:04:13 GMT 2023 , Edited by admin on Sat Dec 16 12:04:13 GMT 2023
|
PRIMARY | |||
|
100000170566
Created by
admin on Sat Dec 16 12:04:13 GMT 2023 , Edited by admin on Sat Dec 16 12:04:13 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
